Biotechnology

New chromosomal abnormalities in AML patients: case report and literature

[ad_1]

“Here we report an unusual association of t(5;17) with t(8;21) in AML and we attempt to discuss the prognosis of this association and then the treatment.”

Credit: 2023 Zahra et al.

“Here we report an unusual association of t(5;17) with t(8;21) in AML and we attempt to discuss the prognosis of this association and then the treatment.”

BUFFALO, NY- July 7, 2023 – A new research paper is published in Genes & Cancer on June 28, 2023 entitled, “Novel t(5;17)(q35;q21) associated with t(8;21)(q22;q22) in patients with acute myeloid leukemia: case report and literature review.”

T(8;21)(q22;q22) with RUNX1-RUNX1T1 rearrangement results is one of the most common cytogenetic abnormalities in acute myeloid leukemia (AML). It is associated with a favorable prognosis. The T(5;17)(q35;q21) is an unusual translocation, splicing the gene for nucleophosmin (NPM) to the α-retinoic acid receptor (RARA) and described primarily in variant acute promyelocytic leukemia (APL).

In the new paper, researchers Kmira Zahra, Wided Cherif, Gereisha Ahmed, Haifa Regaieg, Ben Sayed Nesrine, Monia Zaier, Wided Mootamri, Yosra Ben Youssef, Nejia Brahem, Halima Sennana, And Abderrahim Khelif from Farhat Hached University Hospital-Sousse-Tunisia presents the case of a 19-year-old male patient who developed AML with t(8;21)(q22;q22) related to t(5;17)(q35;21).

Leukemic cell morphology and immunophenotype compatible with AML. The patient received chemotherapy based on cytarabine and anthracycline without all-trans retinoic acid (ATRA) followed by allogeneic stem cell transplantation in first remission. To the investigators’ knowledge, this is the first report of an association between rare t(5;17) and t(8;21) translocations in AML.

“In this report, we will discuss the prognosis of this association and its treatment.”

Read more: DOIs: https://doi.org/10.18632/genesandcancer.232

Correspondence: Kimira Zahra – Email: (email protected)

Keywords: acute myeloid leukemia, T (8; 21) (q22; q22), T (5; 17) (q35; q21), NPM1/RARA, allogeneic stem cell transplant

About Genes & Cancer: Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that are directly related to the research field, Genes & Cancer also aims to attract papers in the fields of genomics, drug development and systems biology.

To learn more about Genes & Cancervisit www.genesandcancer.com and connect with us on social media:

  • Twitter
  • Facebook
  • YouTube
  • LinkedIn
  • Instagram

For media inquiries, please contact: (protected e-mail).

Office of the Journal of Genes & Cancer

6666 East Quaker Str., Suite 1C

Orchard Park, New York 14127

Telephone: 1-212-659-5400

###




[ad_2]

Source link

Related Articles

Back to top button